Has German Hernandez, MD received payments from drug or device companies?

Yes. Drug and device makers reported $9,650,329 in general payments to German Hernandez, MD across 3,692 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean German Hernandez, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about German Hernandez, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

German Hernandez, MD

Nephrology · El Paso, TXNPI 1154367704

Payments from drug & device makers

$9,650,329in general payments, 2019–2025

Across 3,692 payments — averaging $2613.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

CSL Behring$2.6M
Astrazeneca UK Limited$2.2M
AstraZeneca$1.5M
Bayer$623K
Akebia Therapeutics Inc$484K
Otsuka Pharmaceutical Development & Commercialization, Inc.$375K
plus $1.9M from 51 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
CSL Behring	68	$2,550,745
Astrazeneca UK Limited	21	$2,159,522
AstraZeneca(2 entities)	333	$1,522,170
Bayer	556	$622,997
Akebia Therapeutics Inc	625	$484,060
Otsuka Pharmaceutical Development & Commercialization, Inc.	7	$374,608
Aurinia Pharma U.S., Inc.	471	$303,215
Otsuka America Pharmaceutical, Inc.	284	$164,318
Travere Therapeutics, Inc.	255	$158,225
Novartis	26	$145,812
Calliditas Therapeutics US Inc.	131	$127,458
Alnylam Pharmaceuticals Inc.	32	$114,675
Sanofi	22	$108,319
Baxter Healthcare	3	$104,306
Vertex	5	$85,400
GSK	83	$72,990
Vifor Pharma, Inc.	186	$71,344
Novo Nordisk AS	152	$70,694
Boehringer Ingelheim International GmbH	22	$63,614
E.r. Squibb & Sons, L.L.C.	8	$50,991
Dynavax Technologies Corporation	37	$50,018
Astrazeneca AB	5	$44,262
Janssen Research & Development, LLC	25	$42,940
Boehringer Ingelheim	60	$41,372
Gilead	4	$23,930
Ardelyx, Inc.	45	$21,673
Amgen(2 entities)	70	$20,695
Lilly USA, LLC	31	$16,070
Apellis Pharmaceuticals, Inc.	9	$12,223
Sanofi US Services Inc.	2	$6,511
Janssen Scientific Affairs, LLC	7	$5,077
Biogen	1	$3,890
Pfizer	3	$1,510
VBI Vaccine (delaware) Inc.	1	$1,305
Novo Nordisk	20	$783
OPKO Pharmaceuticals, LLC	36	$630
Johnson & Johnson	2	$469
Mallinckrodt Hospital Products Inc.	8	$287
Fresenius USA Marketing, Inc.	4	$250
Medtronic	1	$160
Cormedix Inc.	4	$140
Takeda Pharmaceuticals U.S.A., Inc.	4	$108
Inspire Medical Systems, Inc.	1	$101
Scpharmaceuticals Inc.	5	$79
Dexcom, Inc.	3	$58
Merck	2	$52
Kyowa Kirin, Inc.	1	$50
Madrigal Pharmaceuticals	1	$30
Nxstage Medical, Inc.	2	$29
Pharmacosmos Therapeutics Inc.	1	$27
Lexicon Pharmaceuticals, Inc.	1	$26
Daiichi Sankyo Inc.	1	$23
Ultragenyx Pharmaceutical Inc.	1	$22
Mallinckrodt Enterprises LLC	1	$20
Abbott	1	$17
ANI Pharmaceuticals, Inc.	1	$15
Xeris Pharmaceuticals, Inc.	1	$15

How this compares

$9,650,329 in reported general payments places this provider in the 95th percentile of 1,070 nephrology providers in Texas.

See all nephrology providers in Texas →

Medicare billing

Part B allowed, 2024

$130,689

Medicare patients

266

Services billed

976

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other nephrology in El Paso

Simon RodriguezEl Paso$1.9M
Pablo PergolaSan Antonio$14.2M
Sreedhar MandayamHouston$7M
Tahira AlvesSan Antonio$6.1M
Carl DukesSan Antonio$5.9M
Chinonye Ogbonnaya-OdorSan Antonio$4.6M
Marializa BernardoHouston$4.2M
Judith BettsAustin$3.7M
Wesley CalhounSan Antonio$3.5M
Adam FromeThe Woodlands$3.1M

See the full list for Texas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →